This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Aug 21;376(9741):567-8.

doi: 10.1016/S0140-6736(10)60999-3. Epub 2010 Jul 29.

Is cardiometabolic risk improved by weight-loss drugs?

Affiliations

PMID: 20673996
DOI: 10.1016/S0140-6736(10)60999-3

Comment

Is cardiometabolic risk improved by weight-loss drugs?

Arne Astrup. Lancet. 2010.

. 2010 Aug 21;376(9741):567-8.

doi: 10.1016/S0140-6736(10)60999-3. Epub 2010 Jul 29.

Author

Affiliation

¹ Department of Human Nutrition, Faculty of Life Sciences, University of Copenhagen, DK-1958 Frederiksberg, Copenhagen, Denmark. ast@life.ku.dk

PMID: 20673996
DOI: 10.1016/S0140-6736(10)60999-3

No abstract available

PubMed Disclaimer

Comment on

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E; COR-I Study Group. Greenway FL, et al. Lancet. 2010 Aug 21;376(9741):595-605. doi: 10.1016/S0140-6736(10)60888-4. Epub 2010 Jul 29. Lancet. 2010. PMID: 20673995 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information